tldrdailynews.com logo

Merck to Acquire Prometheus Biosciences for $11 Billion

1 min read
Source: Fox Business
Merck to Acquire Prometheus Biosciences for $11 Billion
Photo: Fox Business
TL;DR Summary

Merck & Co. is reportedly in late-stage talks to acquire Prometheus Biosciences Inc., a San Diego-based company that develops immune treatments for diseases including ulcerative colitis and Crohn’s disease. The deal could give Merck promising immune disease treatments as it looks to add new products to its pipeline. However, a deal is not certain and could still fall apart.

Topics:business#acquisition#business#drug-development#immune-diseases#merck#prometheus-biosciences
Share this article
  1. Merck in talks to acquire Prometheus Biosciences: report  Fox Business
  2. Merck in Late-Stage Talks to Acquire Prometheus Biosciences - WSJ  The Wall Street Journal
  3. Merck to buy Prometheus Biosciences for about $11 bln  Reuters.com
  4. Merck Agrees to Buy Prometheus for $200 Per Share in Cash  Bloomberg
  5. Merck to buy Prometheus Biosciences for about $11 billion By Reuters  Investing.com
  6. View Full Coverage on Google News

Reading Insights

Total Reads

0

Unique Readers

26

Time Saved

1 min

vs 2 min read

Condensed

81%

317 → 59 words

Want the full story? Read the original article

Read on Fox Business